ALSO NOTED: IMPAX names new CEO; deCODE launches trial; and much more...

> Raven biotechnologies had reported positive early results of a Phase I clinical trial of RAV12, its lead therapeutic antibody in development for the treatment of adenocarcinomas. Release

> In Mexico and Guatemala, the Iomai Corporation has begun enrollment in a Phase II trial to test its vaccine patch for travelers' diarrhea. Release 

> Iceland-based deCODE Genetics has begun enrolling patients in a Phase I trial of  DG051, the company's follow-on developmental compound for the prevention of heart attack. Release

> Chutes & Ladders: IMPAX Laboratories has named Larry Hsu CEO. He is replacing current CEO Barry R. Edwards, who is resigning. Release

> And Finally... There are promising developments in the search for a skin test for Alzheimer's disease. Report